Viridian Therapeutics' stock jumps after Phase III trial met all endpoints [Yahoo! Finance]
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Yahoo! Finance
Previously known as VRDN-001, veligrotug won in the Phase III THRIVE trial (NCT05176639). It also boasted positive safety data in patients with TED, which is also known as Graves' disease. The news saw the Massachusetts-based company's stock price rise by 32% on 10 September, having closed at $14.19 on 9 September and $18.75 on 10 September. The trial met the primary and all secondary endpoints at 15 weeks after five infusions of veligrotug, showing highly statistically significant improvements in all the measured signs and symptoms of TED. Veligrotug additionally showed a rapid onset of action, with more than half of veligrotug-treated patients achieving a proptosis response after just one infusion. After 15 weeks, the treatment group saw a 70% proptosis responder rate (PRR) compared to 5% in the placebo arm. There was a 2.9mm mean reduction in proptosis from baseline in patients receiving veligrotug, compared with a 0.5mm reduction in patients receiving a placebo. Patients
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics, Inc. (VRDN): This Small-Cap Stock Is Ready To Explode [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at HC Wainwright from $27.00 to $34.00. They now have a "buy" rating on the stock.MarketBeat
- Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.MarketBeat
- Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn DataBusiness Wire
VRDN
Earnings
- 11/12/24 - Miss
VRDN
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- VRDN's page on the SEC website